Literature DB >> 32818394

Identification of Streptococcus suis Meningitis by Direct Triplex Real-Time PCR, Burkina Faso.

Mahamoudou Ouattara, Mamadou Tamboura, Dinanibe Kambire, Mahamoudou Sanou, Kalifa Ouattara, Malika Congo, Adama Kaboré, Soufiane Sanou, Elie Kabré, Sable Sharpley, Theresa Tran, Stephanie Schwartz, Soumeya Ouangraoua, Abdoul-Salam Ouedraogo, Lassana Sangaré, Rasmata Ouedraogo-Traore, Cynthia G Whitney, Bernard Beall.   

Abstract

Meningitis confirmation in Burkina Faso uses PCR for detecting Streptococcus pneumoniae, Neisseria meningitidis, or Hemophilus influenzae. We identified 38 cases of meningitis among 590 that were PCR-positive for 3 nonpneumococcal streptococcal pathogens, including 21 cases of Streptococcus suis. Among the country's 13 regions, 10 had S. suis-positive cases.

Entities:  

Keywords:  Burkina Faso; Streptococcus agalactiae; Streptococcus pyogenes; Streptococcus suis; bacteria; direct real-time PCR; infection; meningitis; meningitis/encephalitis; streptococci; zoonoses; zoonotic diseases

Mesh:

Year:  2020        PMID: 32818394      PMCID: PMC7454097          DOI: 10.3201/eid2609.200203

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Streptococcus suis is a commensal organism of the upper respiratory tract of pigs that can occasionally cause severe invasive infections in these animals (,). The bacterium also can infect humans who have close contact with pigs or pork products, leading to serious diseases such as meningitis, endocarditis, and sepsis (). S. suis can survive in dust, manure, and pig carcasses for days or even weeks under optimal conditions; therefore, the working environments in slaughterhouses and farms can be a source of human infection (,). Meningitis is the most common clinical manifestation of S. suis infection in humans and has an estimated case-fatality rate of 3% (). Whereas this zoonotic pathogen is among the leading causes of adult meningitis in some countries of Southeast Asia (), its incidence in Africa is largely unknown. We report 21 retrospectively confirmed cases of S. suis meningitis in Burkina Faso.

The Study

Burkina Faso conducts nationwide case-based surveillance for bacterial meningitis. Cerebrospinal fluid (CSF) samples collected from patients with suspected meningitis are sent to 1 of 5 national laboratories for confirmation by culture and real-time PCR testing (). Because of multiple challenges encountered by the laboratories in isolating bacteria from CSF, the confirmation of meningitis cases relies heavily on molecular detection (). The real-time PCR assay currently used at the national laboratories only detects Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Between 2015 and 2018, the national laboratories tested 7,174 CSF samples from patients with suspected meningitis nationwide. Of these, 4,930 (68.7%) were PCR-negative for S. pneumoniae, N. meningitidis, and H. influenzae. To further investigate suspected meningitis cases that were PCR-negative after testing for the 3 pathogens, a subset of specimens was selected for additional screening based on leukocytes counts >50 cells/mm3. In total, 912 PCR-negative specimens were available for the study; among these, 590 fit the selection criteria. The specimens were retested by using a triplex direct real-time PCR that was designed for the simultaneous detection of Streptococcus agalactiae (group B Streptococcus [GBS]), S. pyogenes (group A Streptococcus [GAS]), and S. suis. The nucleotide sequences and final concentrations of the primers and probes used in this assay (Table 1) were identical to those used in singleplex real-time PCR methods (–), with the exception that FAM was replaced by HEX as the reporter dye for cfb-specific probes for the GBS target and by Cy5 as the reporter dye for spy-specific probes for the GAS target. Each reaction was prepared in a final volume of 25 µL, including 1 µL of each primer and probe, 2 µL of CSF as DNA template, 12.5 µL of PerfeCta MultiPlex qPCR ToughMix mastermix (QuantaBio, https://www.quantabio.com), and 1.5 µL of PCR-grade water. The thermal profile for the real-time PCR runs was 1 cycle of 55°C for 5 min, 1 cycle of 95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min. All specimens were tested by real-time PCR for the presence of the human ribonuclease P (RNaseP) gene to check for the presence of inhibitors. A specimen was considered positive if the cycle threshold (Ct) for 1 of the bacterial targets was <35 and was considered negative if the Ct was >40 for all bacterial targets with Ct <35 for RNaseP. If Ct was between 35 and 40 for the bacterial targets and <35 for RNaseP, the specimen is retested; if the result was reproducible, it was considered positive. The lower limits of detection (LLDs) were determined as previously described (). The LLD of the direct triplex assay (3 CFU/µL for S. suis, 28 CFU/µL for GBS, and 26 CFU/µL for GAS) were compared with the LLD of the triplex assay conducted on DNA extracted from the same serial dilutions (2 CFU/µL for S. suis, 5 CFU/µL for GBS, and 3 CFU/µL for GAS).
Table 1

Sequences and concentrations of primers and probes used to detect Streptococcus suis, S. agalactiae, and S. pyogenes, Burkina Faso*

Target geneForward primer, 5¢ ® 3¢Reverse primer, 5¢ ® 3¢Probe, 5¢ ® 3¢Concentration of oligo per reaction, nM†
cfb (7), GBSGGGAACAGATTATGAAAAACCGAAGGCTTCTACACGACTACCAAAGACTTCATTGCGTGCCAACCCTGAGAC
5¢-HEX; 3¢-BHQ1200/200/200
fbpS (8), S. suisTCCRATRCTGCTCTGCCATTTGATAGTAGAAGTCCAGCARACTAATAGCCC”T”GAAAAMCAGCCACWYTTTGARA
5¢-FAM; 3¢-SpC6; “T” = BHQ1200/200/100
spy (9), GASGCACTCGCTACTATTTCTTACCTCAAGTCACAATGTCTTGGAAACCAGTAATCCGCAAC”T”CATCAAGGATTTCGTTACCA
5¢-Cy-5; 3¢- SpC6; “T” = BHQ2300/300/100
RNaseP (10)AGATTTGGACCTGCGAGCGGAGCGGCTGTCCCACAAGTTTCTGACCTGAAGGCTCTGCGCG
5¢-FAM; 3¢-BHQ1400/400/100

*GAS, group A Streptococcus (Streptococcus pyogenes); GBS, group A Streptococcus (S. agalactiae); RNaseP, human ribonuclease P.
†Concentration of forward primer/reverse primer/probe.

*GAS, group A Streptococcus (Streptococcus pyogenes); GBS, group A Streptococcus (S. agalactiae); RNaseP, human ribonuclease P.
†Concentration of forward primer/reverse primer/probe. Among the specimens tested, 21 were positive for S. suis, 13 for GAS, and 4 for GBS (Table 2). Of the 21 S. suis–positive case-patients, 1 was 4 years of age, 3 were 5–14 years of age, 2 were 15–29 years of age, 9 were 30–49 years of age, and 6 were >50 years of age; 16 (76.2%) were male and 5 (23.8%) were female. Two (9.5%) patients died, 14 recovered, and the outcome for 5 was unknown. Eight (61.5%) of the GAS-positive case-patients were <5 years of age and 5 were 5–14 years of age; 1 (7.7%) patient died, 5 recovered, and the outcome for 7 was unknown. All the GBS-positive case-patients were <6 months of age and all recovered. Median time from symptom onset to CSF collection was 2 days (range 1–10 days) for all the patients.
Table 2

Characteristics of patients with meningitis caused by Streptococcus suis, S. pyogenes, and S. agalactiae, Burkina Faso, 2015–2018*

CharacteristicsPatients infected, no. (%)
All patients, no. (%), n = 590
S. suis, n = 21S. pyogenes, n = 13S. agalactiae, n = 4
Age, y
<51 (4.8)8 (61.5)4 (100)307 (52)
5–143 (14.3)5 (38.5)0168 (28.5)
15–292 (9.5)0064 (10.8)
30–499 (42.8)0037 (6.3)
>50
6 (28.6)
0
0
14 (2.4)
Sex
M16 (76.2)9 (69.2)2 (50)332 (56.3)
F
5 (23.8)
4 (30.8)
2 (50)
258 (43.7)
Year CSF collected
20155 (23.8)1 (7.7)087 (14.7)
20162 (9.5)2 (15.4)0104 (17.6)
20176 (28.6)3 (23.1)2 (50)195 (33.1)
2018
8 (38.1)
7 (53.8)
2 (50)
204 (34.6)
Median leukocytes, cells/mm3 (range)400 (51–6,250)1,000 (53–8,000)1,100 (800–2,400)920 (50–8,000)
Median Ct (range)26.1 (18.13–35.52)25.33 (14.78–34.71)23.47 (17.24−24.23)25.33 (14.78–35.52)

*CSF, cerebrospinal fluid; Ct, cycle threshold.

*CSF, cerebrospinal fluid; Ct, cycle threshold. S. suis–positive cases were found among specimens from rural districts in 10/13 regions of the country with 28% (6/21) from the Centre-Est Region and 19% (4/21) from the Plateau Central Region. All adults with S. suis were farmers. Because of the retrospective detection of the etiology, the extent of any direct exposure of the S. suis–positive patients to pigs or pork products was unknown and attempts to collect additional information from the patients or their families were unsuccessful. Small-scale pig farming is a major economic activity in most parts of Burkina Faso. Although porcine-related occupations, undercooked pork consumption, and exposure to pigs have been identified as major risk factors for S. suis infection (), its occurrence in a wide range of animal species have been reported (). DNA extracted from the S. suis–positive specimens were used for a multiplex conventional PCR for serotype detection (). All the specimens were serotype 2 or 1/2 because the method used here could not clearly differentiate serotypes 2 and 1/2. Bacterial isolates from these cases were not available for further characterization. Serotype 2 is believed to cause 74%–95% of human cases of S. suis infections reported worldwide, but serotype 1/2 has not been reported to cause disease in humans (,).

Conclusions

Limited data are available regarding the incidence of streptococcal infections in Africa, and the disease burden likely is underestimated, especially for disease caused by S. suis. Two reported studies conducted in Togo identified 16 human cases of S. suis meningitis during 2010–2015 caused by serotype 2 (,). Another recent study in Madagascar described 2 human cases of S. suis meningitis, also caused by serotype 2 (). Our study reports 21 cases of S. suis meningitis from 2015–2018 in Burkina Faso. S. suis infections more commonly are observed in adult males and are directly correlated with occupational exposure to pigs or pork products (,,). All adult cases reported here were farmers, although their exposure to pigs or pork was unknown. The presence of children among the patients in this study and in previous studies () indicates that older children also should be considered at risk. Finding 21 cases of this outbreak-prone zoonotic pathogen in this study raises concern about the incidence of S. suis disease in Burkina Faso and in other parts of Africa where pigs are raised. Prospective surveillance for S. suis could help identify farming communities where measures to prevent disease and its potential socioeconomic damages are needed.
  15 in total

1.  Triplex real-time PCR assay for the detection of Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae directly from clinical specimens without extraction of DNA.

Authors:  Mahamoudou Ouattara; Melissa J Whaley; Laurel T Jenkins; Stephanie B Schwartz; Rasmata Ouédraogo Traoré; Seydou Diarra; Jean-Marc Collard; Claudio T Sacchi; Xin Wang
Journal:  Diagn Microbiol Infect Dis       Date:  2018-10-16       Impact factor: 2.803

2.  Streptococcus suis serotyping by a new multiplex PCR.

Authors:  Anusak Kerdsin; Yukihiro Akeda; Rujirat Hatrongjit; Unchaya Detchawna; Tsutomu Sekizaki; Shigeyuki Hamada; Marcelo Gottschalk; Kazunori Oishi
Journal:  J Med Microbiol       Date:  2014-04-02       Impact factor: 2.472

Review 3.  Streptococcus suis: a new emerging or an old neglected zoonotic pathogen?

Authors:  Marcelo Gottschalk; Jianguo Xu; Cynthia Calzas; Mariela Segura
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

4.  Species-specific real-time PCR assay for the detection of Streptococcus suis from clinical specimens.

Authors:  Velusamy Srinivasan; Lesley McGee; Berthe-Marie Njanpop-Lafourcade; Jennifer Moïsi; Bernard Beall
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-18       Impact factor: 2.803

Review 5.  Streptococcus suis, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing.

Authors:  Guillaume Goyette-Desjardins; Jean-Philippe Auger; Jianguo Xu; Mariela Segura; Marcelo Gottschalk
Journal:  Emerg Microbes Infect       Date:  2014-06-18       Impact factor: 7.163

6.  Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine-Burkina Faso, 2011-2013.

Authors:  Dinanibè Kambiré; Heidi M Soeters; Rasmata Ouédraogo-Traoré; Isaïe Medah; Lassana Sangare; Issaka Yaméogo; Guetawendé Sawadogo; Abdoul-Salam Ouédraogo; Soumeya Hema-Ouangraoua; Lesley McGee; Velusamy Srinivasan; Flavien Aké; Malika Congo-Ouédraogo; Soufian Sanou; Absatou Ky Ba; Ryan T Novak; Chris Van Beneden
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

7.  Human meningitis due to Streptococcus suis in Lomé, Togo: a case report.

Authors:  Mireille Prince-David; Mounerou Salou; Corinne Marois-Créhan; Komi Assogba; Céline Plainvert; Koffi A Balogou; Claire Poyart; Asmaa Tazi
Journal:  BMC Infect Dis       Date:  2016-11-08       Impact factor: 3.090

8.  Novel Streptococcus suis Sequence Type 834 among Humans, Madagascar.

Authors:  Mihaja Raberahona; Saïda Rasoanandrasana; Vonintsoa Lalaina Rahajamanana; Felana Ranaivo-Rabetokotany; Volatiana Andriananja; Fetra Angelot Rakotomalala; Mamy Jean de Dieu Randria; Luc Rakotovao; Corinne Marois-Créhan; Véronique Tocqueville; Fabrice Touzain; Mala Rakoto-Andrianarivelo
Journal:  Emerg Infect Dis       Date:  2018-02       Impact factor: 6.883

9.  Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus.

Authors:  Shannon L Emery; Dean D Erdman; Michael D Bowen; Bruce R Newton; Jonas M Winchell; Richard F Meyer; Suxiang Tong; Byron T Cook; Brian P Holloway; Karen A McCaustland; Paul A Rota; Bettina Bankamp; Luis E Lowe; Tom G Ksiazek; William J Bellini; Larry J Anderson
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

10.  Identification of Streptococcus suis Meningitis through Population-Based Surveillance, Togo, 2010-2014.

Authors:  Haoua Tall; Berthe-Marie Njanpop-Lafourcade; Didier Mounkoro; Loukoumane Tidjani; Kodjo Agbenoko; Issifou Alassani; Moussa Amidou; Stanislas Tamekloe; Kenneth G Laing; Adam A Witney; Jason Hinds; Mark P G van der Linden; Bradford D Gessner; Jennifer C Moïsi
Journal:  Emerg Infect Dis       Date:  2016-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.